All news from Immuno Haematology & Blood Transfusion

Immune hematology

Lymph Node Cells that may Play Important Roles in Immune Tolerance

Aire expression in the thymus contributes to immune tolerance by eliminating auto-reactive T cells; insufficient elimination causes autoimmune disorders. The Aire gene was thought to be expressed only in the thymus, but recently, researchers reported Aire expression in peripheral lymph nodes. Researchers have now identified the cells expressing Aire in 0.01% of lymph node cells…

Immune haematology

Study Opens Window into Immune Microenviroment

The first comprehensive study of immune cell types in pre and post chemotherapy cancer tissues points up a host of targets for new or existing cancer drugs that could improve patients’ sensitivity to both chemotherapy and immunotherapy. Results from the SWOG Cancer Research Network study appear in the latest issue of the Journal for ImmunoTherapy…

Immune haematology

Immune Cell Populations Points to New Targets For Immunotherapy

The recent emergence of immunotherapy has marked a sea change in research and care for many forms of cancer, bringing new hope to patients and families around the world. For those who respond to treatment, the results can be dramatic. Activation of a patient’s immune system against cancer can kill or shrink tumors and, in…

Immune haematology

Immune Cells Key to Predicting Cancer Outcomes

Scientists have identified key changes in immune cells within cancerous tumours that could help improve the development of treatments. The study also found a set of genes that are expressed at high levels in breast cancer tumours and linked to more aggressive cancer types. Researchers say the discoveries offer clues to diagnosis and predicting patient survival and…

Immunehaematolgy

Patients on Immunotherapies Should Consume More Fiber

On the other hand, patients on a fiber-rich diet showed a five-fold increase in response. The study is present on April 2, 2019, at the American Association for Cancer Research (AACR) Annual Meeting 2019. The pioneering study was carried out by the Parker Institute for Cancer Immunotherapy (PICI) and The University of Texas MD Anderson…

Immune hematology

Genome Sciences Receives Grant for Infectious Disease

The Institute for Genome Sciences (IGS) at the University of Maryland School of Medicine (UMSOM) was awarded $17.5 million from the National Institute of Allergy and Infectious Diseases (NIAID) to fund the IGS Genome Center for Infectious Diseases (GCID) for another five years. Because The Principal Investigator and Administrative Core Director for the grant, which…

Immunohaematology

Is Your Melanoma Hot Enough for Immunotherapy

Melanomas tend to be “hot” or “cold if they’re hot; immunotherapy lights melanoma tumors like beacons for elimination by the immune system; but 40-50% of melanomas are cold, making them invisible to the immune system, and patients with cold tumors tend to show little benefit from immunotherapies. The problem is that it’s been impossible to…

Immunehaematology

Immune Cells Help Tumors Escape Body's Defenses

New research from the University of Pittsburgh School of Medicine and the UPMC Hillman Cancer Center sheds light on how tumors use the body’s regulators of immunity for their own benefit. Published today in Nature Immunology, the findings could be used to develop the next generation of immune therapies to fight various cancers. Revolutionized cancer care…

Immunehaematology

Immunotherapy Combination Shrinks Rare Neuroendocrine Cancer

A combination of two common immunotherapy drugs shrinks rare, aggressive neuroendocrine tumors, according to new research results presented at the American Association for Cancer Research Annual Meeting 2019, held March 29-April 3 in Atlanta. Results from the SWOG Cancer Research Network trial known as DART, short for Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors,…

Immune haematology

Immune Checkpoint Inhibitor Combo Efficacious For Patients

A combination of the anti-CTLA-4 immunotherapeutic ipilimumab and the anti-PD-1 immunotherapeutic nivolumab (Opdivo) showed clinical benefit among patients with rare, high-grade neuroendocrine carcinoma, according to results from the DART phase II clinical trial presented at the AACR Annual Meeting 2019, March 29-April 3. Performing clinical trials “Rare tumor types, as an aggregate, represent nearly a…

immuneheamatology

Promising Target For Cancer Immunotherapy

Researchers have shown that cancer immunotherapy targeting the tumor biomarker epithelial cell adhesion molecule (EpCAM) is safe and nontoxic in mice and can significantly delay tumor formation and growth. EpCAM is overexpressed in various tumor types, circulating tumor cells, and tumor stem cells, giving these findings broad implications. The study design and results are publish…

Immune hematology

Immune Cells Hinder Front line Chemotherapy Drug In Pancreatic Cancer

A front line chemotherapy drug given to patients with pancreatic cancer is made less effective because similar compounds released by tumor-associated immune cells block the drug’s action, research led by the University of Michigan Rogel Cancer Center found. The chemotherapy drug gemcitabine is an anti-metabolite. Drug in malignant cells It’s similar to normal metabolites taken…